Dr. C. Ola Landgren (IMAGE)

University of Miami Miller School of Medicine

Dr. C. Ola Landgren

Caption

The prediction model for individualized risk in newly diagnosed multiple myeloma, or IRMMa, improves on previous prognostic tools because it takes into account the biology of patients’ tumors, said Dr. C. Ola Landgren, chief of the Division of Myeloma and director of the Sylvester Myeloma Institute. This is important in many cancers, but especially in multiple myeloma, which is highly variable.

Credit

Photo by Sylvester

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.